CN115590985B - Sterile medical ultrasonic coupling agent and preparation method thereof - Google Patents
Sterile medical ultrasonic coupling agent and preparation method thereof Download PDFInfo
- Publication number
- CN115590985B CN115590985B CN202111578921.2A CN202111578921A CN115590985B CN 115590985 B CN115590985 B CN 115590985B CN 202111578921 A CN202111578921 A CN 202111578921A CN 115590985 B CN115590985 B CN 115590985B
- Authority
- CN
- China
- Prior art keywords
- medical ultrasonic
- sterile medical
- coupling agent
- carbomer
- sterile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000007822 coupling agent Substances 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title abstract description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000004202 carbamide Substances 0.000 claims abstract description 14
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 11
- 108010046334 Urease Proteins 0.000 claims abstract description 11
- 229960001631 carbomer Drugs 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000003906 humectant Substances 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims abstract description 6
- 239000008213 purified water Substances 0.000 claims abstract description 6
- 239000003755 preservative agent Substances 0.000 claims abstract description 5
- 230000002335 preservative effect Effects 0.000 claims abstract description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 8
- 230000008719 thickening Effects 0.000 claims description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 4
- 229960005323 phenoxyethanol Drugs 0.000 claims description 4
- 238000002604 ultrasonography Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 239000003349 gelling agent Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 230000001954 sterilising effect Effects 0.000 abstract description 10
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 6
- 230000001050 lubricating effect Effects 0.000 abstract description 4
- GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 abstract description 3
- 238000003384 imaging method Methods 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 231100000344 non-irritating Toxicity 0.000 abstract description 2
- 231100000252 nontoxic Toxicity 0.000 abstract description 2
- 230000003000 nontoxic effect Effects 0.000 abstract description 2
- 239000000126 substance Substances 0.000 description 6
- 238000000354 decomposition reaction Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- ZEYHEAKUIGZSGI-UHFFFAOYSA-N 4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- VVOAZFWZEDHOOU-UHFFFAOYSA-N magnolol Chemical compound OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 101100515516 Arabidopsis thaliana XI-H gene Proteins 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000012009 microbiological test Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000009974 thixotropic effect Effects 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Acoustics & Sound (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a sterile medical ultrasonic couplant and a preparation method thereof, wherein the sterile medical ultrasonic couplant comprises the following components: 0.3-0.8% carbomer, 5-15% humectant, 0.1-1% preservative, 0.5-5% urea, 0.001-0.01% urease and the balance purified water. The invention also discloses a preparation method of the aseptic medical ultrasonic coupling agent. The sterile medical ultrasonic couplant is colorless, nontoxic and non-irritating, has good thermal stability, good lubricating performance and clear ultrasonic imaging, and can meet various requirements of the sterile medical ultrasonic couplant of medical industry standard YY0299-2016 of medical ultrasonic couplant. In addition, the sterile medical ultrasonic coupling agent has the advantages of simple manufacturing process, no need of vacuumizing to remove bubbles, no need of cobalt-60 irradiation sterilization and other processes, simple manufacturing process, low cost and easy market popularization and application.
Description
Technical Field
The invention belongs to the technical field of medical ultrasonic diagnosis and detection, and particularly relates to a sterile medical ultrasonic coupling agent and a preparation method thereof.
Technical Field
Medical ultrasound examination is a visual medical imaging diagnosis technology based on ultrasonic waves, which has been applied only in the 20 th century, and has been widely used in the current medicine, because ultrasonic waves can generate reflection phenomena when being incident on the interface between two different media, and reduce the size of sound energy penetrating into the other medium, filling an intermediate substance between the body of a patient and a probe becomes a necessary means for reducing the loss of sound energy, the intermediate substance is called a medical ultrasonic couplant, and gradually becomes one of the most frequently used medical supplies in clinic, and in practical application, the ultrasonic couplant has a plurality of performance requirements: 1. no irritation to skin, and no anaphylaxis caused by long-time contact; 2. the thixotropic property is good, and the air is thoroughly removed; 3. the sound velocity is proper, the attenuation coefficient is small, the acoustic impedance is moderate, so that the definition of ultrasonic imaging is improved; 4. good lubricating performance, proper viscosity, no flow and easy erasure; 5. can wet skin and is not easy to dry; 6. has thermal stability, and the adhesive force is not reduced under clinical conditions; 7. has no corrosion to the ultrasonic probe.
To date, the medical industry standard YY0299-2016 named as medical ultrasonic couplant is established in China in the couplant industry, and the standard specifically limits and prescribes the classification and the use as well as the components of the medical ultrasonic couplant, and provides related technical requirements and test methods for products.
According to the classification of medical ultrasonic couplants, at present, the non-sterile medical ultrasonic couplants in the market are more in variety, most of the non-sterile products are also sterile products, for example, CN105983107A provides a novel medical sterilizing ultrasonic couplant, takes magnolol as a main sterilizing component, and takes eugenol, anisic acid, dipotassium glycyrrhizinate and vanillin for synergistic sterilization; for example, CN104189927A is compounded by 6 Chinese herbal medicine essential oils to achieve the sterilization effect, and the mixed smell of the various Chinese herbal medicine essential oils is mixed, and the preparation process is complex; and as another example, the chemical components are used as bactericides: CN101219223A uses (0.2% -2%) 2, 4-trichloro-2-hydroxydiphenyl ether as sterilizing component, can not be biodegraded, and has a large amount of chemical sterilizing agent, and can remain on skin after ultrasonic diagnosis, thus having certain stimulation effect on skin.
Meanwhile, the aseptic medical ultrasonic couplant meeting the requirements of medical ultrasonic couplant is relatively few.
Disclosure of Invention
The invention provides a sterile medical ultrasonic couplant and a preparation method thereof, aiming at the defects of the existing medical ultrasonic couplant products. The invention adopts the raw materials meeting the standard requirements and is assisted by a physical and chemical combination mode, thereby meeting the requirements of medical ultrasonic couplant.
The invention is realized in such a way that a sterile medical ultrasonic coupling agent comprises the following components in percentage by weight:
carbomer 0.3-0.8%,
5-15% of humectant,
preservative phenoxyethanol 0.1-1%
Urea 0.5-5%
Urease 0.001-0.01%
Purifying water, and the balance.
The carbomer is a water-soluble gelling agent.
The sterile medical ultrasonic couplant adopts urea as a pH adjusting and skin care agent.
The aseptic medical ultrasonic couplant comprises the following components: the wetting agent is one or more of glycerol, propylene glycol and polyethylene glycol.
A preparation method of an aseptic medical ultrasonic coupling agent comprises the following steps:
(1) Carbomer is weighed according to the proportion and added into purified water to be stirred and dissolved for 40 to 60 minutes, thus obtaining solution A.
(2) And adding the humectant, the preservative and the urea in the proportion into the solution A, and uniformly stirring to obtain the solution B.
(3) Adding urease into the solution B, stirring for 10 minutes, and standing to obtain the solution C.
(4) And (3) filling the liquid C, and then, thickening the liquid C for 30 to 60 minutes at the temperature of 75 to 85 ℃ to obtain the sterile medical ultrasonic coupling agent.
Compared with the prior art, the following test examples prove that the invention has the following advantages:
the invention adopts urea as a pH regulator, the urea is used as a skin moisturizer, naturally exists in the horny layer of skin, belongs to the main component of natural skin moisturizing factor NMF, and has double effects of moisturizing and softening the horny layer of skin. The principle of the invention is that urea is decomposed into ammonia and carbon dioxide under the action of urease to finally form ammonium bicarbonate, so that the pH value of the solution is kept between neutral 6.5 and 7.5, the aim of thickening a system can be achieved, and the skin cannot be stimulated.
The invention adopts urease as a urea decomposition catalyst, and the urease is used as an absolute and specific urea decomposition enzyme widely existing in microorganisms and animal and plant tissues, so that the urea can be rapidly catalyzed and decomposed, the activity of the urease can be controlled by pH and temperature, the pH of an initial system is lower than 3.0, the decomposition speed is very slow, and the decomposition speed can be accelerated when the temperature is increased, thereby achieving the purpose of controlling the thickening time and the steps.
The invention adopts the production process of filling before thickening, because the viscosity of the medical ultrasonic coupling agent is very high, the requirement on filling equipment is high in actual production, and bubbles are easy to generate during filling, so that a degassing device is needed.
The invention adopts a physical and chemical combination mode that the final packaging product is kept for 30-60 minutes at 75-85 ℃ for thickening and sterilizing, does not need cobalt-60 irradiation sterilization, reduces the sterilization treatment difficulty and improves the application range of the product.
The medical ultrasonic couplant can meet various requirements of the medical industry standard YY0299-2016 of medical ultrasonic couplant, and has simple manufacturing process and no need of vacuumizing, bubble removing and other processes.
Detailed Description
The invention will be further illustrated with reference to specific examples. These examples should be construed as merely illustrative of the present invention and not limiting the scope of the present invention. Various changes and modifications to the present invention may be made by one skilled in the art after reading the description herein, and such equivalent changes and modifications are intended to fall within the scope of the present invention as defined in the appended claims.
Example 1
The preparation process of the sterile medical ultrasonic coupling agent comprises the following steps:
(1) 4kg of carbomer was weighed and added to 873kg of purified water, and the mixture was dissolved by stirring for 40 minutes to obtain solution A.
(2) Weighing 100kg of glycerol, 8kg of phenoxyethanol and 15kg of urea, adding into the solution A, and stirring uniformly to obtain solution B.
(3) 10g of urease was added to the solution B, and after stirring for 10 minutes, the mixture was allowed to stand to obtain a solution C.
(4) And (3) filling the liquid C, and then, thickening the liquid C at 78 ℃ for 60 minutes to obtain the sterile medical ultrasonic coupling agent.
Example 2
The preparation process of the sterile medical ultrasonic coupling agent comprises the following steps:
(1) 7kg of carbomer is weighed and added into 900kg of purified water to be stirred and dissolved for 60 minutes, thus obtaining solution A.
(2) Weighing 50kg of glycerol, 3kg of phenoxyethanol and 40kg of urea, adding into the solution A, and stirring uniformly to obtain solution B.
(3) 50g of urease was added to the solution B, and after stirring for 10 minutes, the mixture was allowed to stand to obtain a solution C.
(4) And (3) filling the liquid C, and then, thickening the liquid C at 82 ℃ for 30 minutes to obtain the sterile medical ultrasonic coupling agent.
Test example 1-microbiological test:
taking the aseptic medical ultrasonic couplant samples of the above embodiments, and according to the inspection results of the 'aseptic inspection method' of the appendix XI H of 2010 edition of the pharmacopoeia of the people's republic of China', the blank control tube is aseptically grown, and the results conform to the regulations of the aseptic inspection method.
Test example 2-performance test:
taking the aseptic medical ultrasonic couplant samples of the embodiments, and detecting the main performances of the aseptic medical ultrasonic couplant samples to show that: the acoustic resistance (35 ℃) is 1560-1580 m/s, the acoustic attenuation (35 ℃) is less than or equal to 0.05 dB/(cm.MHz), the pH value is 6.7-7.2, and all indexes meet the requirements of the medical industry standard YY0299-2016 of medical ultrasonic couplant. The ultrasonic probe field simulation experiment shows that: good lubricating performance and clear images.
In conclusion, the sterile medical ultrasonic couplant is colorless, nontoxic, non-irritating, good in thermal stability, good in lubricating performance and clear in ultrasonic imaging, and can meet various requirements of the sterile medical ultrasonic couplant of medical industry standard YY0299-2016 of medical ultrasonic couplant. In addition, the sterile medical ultrasonic coupling agent has the advantages of simple manufacturing process, no need of vacuumizing to remove bubbles, no need of cobalt-60 irradiation sterilization and other processes, simple manufacturing process, low cost and easy market popularization and application.
Claims (3)
1. The aseptic medical ultrasonic coupling agent is characterized by comprising the following components in percentage by weight:
carbomer 0.3-0.8%,
5-15% of humectant,
0.1 to 1 percent of preservative phenoxyethanol,
urea 0.5-5 wt%,
urease 0.001-0.01%,
purified water, the balance,
the carbomer is a water-soluble gelling agent, and the carboxyl content of the carbomer is 56.0-68.0%.
2. The sterile medical ultrasound couplant of claim 1, wherein: the humectant is one or more of glycerol, propylene glycol and polyethylene glycol.
3. A method for preparing a sterile medical ultrasound couplant according to any of claims 1-2 and comprising the steps of:
(1) Weighing carbomer according to the proportion, adding the carbomer into purified water, stirring and dissolving for 40-60 minutes to obtain solution A;
(2) Adding a proportioning humectant, a preservative and urea into the solution A, and uniformly stirring to obtain solution B;
(3) Adding urease into the solution B, stirring for 10 minutes, and standing to obtain solution C;
(4) And (3) filling the liquid C, and then, thickening the liquid C for 30 to 60 minutes at the temperature of 75 to 85 ℃ to obtain the sterile medical ultrasonic coupling agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111578921.2A CN115590985B (en) | 2021-12-22 | 2021-12-22 | Sterile medical ultrasonic coupling agent and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111578921.2A CN115590985B (en) | 2021-12-22 | 2021-12-22 | Sterile medical ultrasonic coupling agent and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115590985A CN115590985A (en) | 2023-01-13 |
| CN115590985B true CN115590985B (en) | 2024-04-12 |
Family
ID=84841800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111578921.2A Active CN115590985B (en) | 2021-12-22 | 2021-12-22 | Sterile medical ultrasonic coupling agent and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115590985B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101966134A (en) * | 2010-09-28 | 2011-02-09 | 广东海洋大学 | Liquid soap with sterilizing and skin protecting functions and preparation method thereof |
| CN104208726A (en) * | 2014-02-28 | 2014-12-17 | 张维芬 | Chitosan quaternary ammonium salt couplant and preparation method thereof |
| CN104721845A (en) * | 2015-03-13 | 2015-06-24 | 湖北大学 | Disinfecting and sterilizing medical ultrasonic coupling agent with moisturizing and skin-moistening effects and preparation method of disinfecting and sterilizing medical ultrasonic coupling agent |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9615750B2 (en) * | 2012-06-14 | 2017-04-11 | Seno Medical Instruments, Inc. | Methods and compositions for carrier agents and clearing agents used in optoacoustic imaging systems |
-
2021
- 2021-12-22 CN CN202111578921.2A patent/CN115590985B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101966134A (en) * | 2010-09-28 | 2011-02-09 | 广东海洋大学 | Liquid soap with sterilizing and skin protecting functions and preparation method thereof |
| CN104208726A (en) * | 2014-02-28 | 2014-12-17 | 张维芬 | Chitosan quaternary ammonium salt couplant and preparation method thereof |
| CN104721845A (en) * | 2015-03-13 | 2015-06-24 | 湖北大学 | Disinfecting and sterilizing medical ultrasonic coupling agent with moisturizing and skin-moistening effects and preparation method of disinfecting and sterilizing medical ultrasonic coupling agent |
Non-Patent Citations (1)
| Title |
|---|
| 卡波姆水凝胶的处方筛选与质量考察;郑增娟等;《医药导报》;20150228;第34卷(第2期);第244-248页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115590985A (en) | 2023-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6776757B2 (en) | In vivo biocompatible acoustic coupling media | |
| CN100542615C (en) | Has medical ultrasonic coupling agent of disinfecting and sterilizing functions and preparation method thereof | |
| CN105194697B (en) | A kind of medical ultrasonic coupling agent and preparation method thereof | |
| CN101716354A (en) | Ultrasonic coupling agent and application thereof | |
| CN102580121B (en) | Medical disinfection coupling agent | |
| CN101724164A (en) | Method for preparing cross-linked hyaluronic acid | |
| CN102580124B (en) | Medical disinfecting ultrasound gel composition and preparation method | |
| CN104189927B (en) | A kind of ultrasonic coupling agent | |
| CN106039330A (en) | Antibacterial medical ultrasonic coupling agent containing traditional Chinese medicine ingredients and preparation method thereof | |
| WO2015027752A1 (en) | Antibacterial medical ultrasonic coupling agent and preparation method thereof | |
| TWI387620B (en) | Method for producing cross-linked hyaluronic acid | |
| CN102580122B (en) | Method for preparing medical disinfection couplant | |
| CN115590985B (en) | Sterile medical ultrasonic coupling agent and preparation method thereof | |
| CN104771791A (en) | Water-soluble aseptic medical multifunctional lubricant and preparation method thereof | |
| CN106540281A (en) | B ultrasonic couplant and its preparation technology | |
| CN104399093A (en) | Medical ultrasonic coupling agent and preparation method thereof | |
| CN105031674A (en) | Disinfectant medical ultrasonic coupling agent and production process thereof | |
| EP1671656A1 (en) | Gels composed of glycols and/or polyols and PVP as in-vivo biocompatible acoustic couplants | |
| CN116549675A (en) | Non-irritating medical ultrasonic coupling agent and preparation method thereof | |
| CN110585450A (en) | Medical disinfection sterilization type ultrasonic coupling agent | |
| WO2007073643A1 (en) | Ultrasonic coupling agent and its preparation process and packaging container contg.same | |
| CN107510851B (en) | Medical ultrasonic coupling pad and preparation method thereof | |
| CN106581780B (en) | Lubricant as well as preparation method and application thereof | |
| CN104888237A (en) | Medical sterilization ultrasound coupling agent and preparation method thereof | |
| CN117679537B (en) | Medical sterile ultrasonic coupling agent and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |